Charles Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles Choi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Michael N. Nitabach
Department of Cellular and Molecular Physiology, Department of Genetics, Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT 06520, USA
3 shared publications- Michael N. Nitabach
Yale University
3 shared publications Ellena v. McCarthy
Department of Cellular and Molecular Physiology, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
2 shared publicationsJean-Philippe Fortin
Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
2 shared publicationsAlan S. Kopin
Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
1 shared publication- Alan S. Kopin
Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts (B.J., K.G., B.N.H, M.B., A.S.K.); and Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (B.J., M.B., A.S.K.).
1 shared publication
Latest Publications
- Open Access
- 1 May 2013
- Published by American Physiological Society in Physiology
- Vol. 28 (3) , 164-171
Membrane-Tethered Ligands: Tools for Cell-Autonomous Pharmacological Manipulation of Biological Circuits
Detection of secreted signaling molecules by cognate cell surface receptors is a major intercellular communication pathway in cellular circuits that control biological processes. Understanding the biological significance of these connections would allow us to understand how cellular circuits operate as a whole. Membrane-tethered ligands are recombinant transgenes with structural modules that allow them to act on cell-surface receptors and ion channel subtypes with pharmacological specificity in a cell-autonomous manner. Membrane-tethered ligands have been successful in the specific manipulation of ion channels as well as G-protein-coupled receptors, and, in combination with cell-specific promoters, such manipulations have been restricted to genetically defined subpopulations within cellular circuits in vivo to induce specific phenotypes controlled by those circuits. These studies establish the membrane-tethering approach as a generally applicable method for dissecting neural and physiological circuits.
- 1 May 2013
- Published by American Physiological Society in Physiology
- Vol. 28 (3) , 164-171
Open AccessMembrane-Tethered Ligands: Tools for Cell-Autonomous Pharmacological Manipulation of Biological Circuits
Detection of secreted signaling molecules by cognate cell surface receptors is a major intercellular communication pathway in cellular circuits that control biological processes. Understanding the biological significance of these connections would allow us to understand how cellular circuits operate as a whole. Membrane-tethered ligands are recombinant transgenes with structural modules that allow them to act on cell-surface receptors and ion channel subtypes with pharmacological specificity in a cell-autonomous manner. Membrane-tethered ligands have been successful in the specific manipulation of ion channels as well as G-protein-coupled receptors, and, in combination with cell-specific promoters, such manipulations have been restricted to genetically defined subpopulations within cellular circuits in vivo to induce specific phenotypes controlled by those circuits. These studies establish the membrane-tethering approach as a generally applicable method for dissecting neural and physiological circuits.
- Open Access
- 1 August 2012
- Published by Elsevier in Cell Reports
- Vol. 2 (2) , 332-344
Autoreceptor Control of Peptide/Neurotransmitter Corelease from PDF Neurons Determines Allocation of Circadian Activity in Drosophila
- 1 August 2012
- Published by Elsevier in Cell Reports
- Vol. 2 (2) , 332-344
Open AccessAutoreceptor Control of Peptide/Neurotransmitter Corelease from PDF Neurons Determines Allocation of Circadian Activity in Drosophila
- 1 April 2010
- Published by Elsevier in Current Biology
- Vol. 20 (7) , R322-R324
Circadian Biology: Environmental Regulation of a Multi-Oscillator Network
- 1 April 2010
- Published by Elsevier in Current Biology
- Vol. 20 (7) , R322-R324
Circadian Biology: Environmental Regulation of a Multi-Oscillator Network
- 1 July 2009
- Published by Elsevier in Current Biology
- Vol. 19 (14) , 1167-1175
Cellular Dissection of Circadian Peptide Signals with Genetically Encoded Membrane-Tethered Ligands
- 1 July 2009
- Published by Elsevier in Current Biology
- Vol. 19 (14) , 1167-1175
Cellular Dissection of Circadian Peptide Signals with Genetically Encoded Membrane-Tethered Ligands
- 12 May 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (19) , 8049-8054
Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function
Class B1 (secretin family) G protein-coupled receptors (GPCRs) modulate a wide range of physiological functions, including glucose homeostasis, feeding behavior, fat deposition, bone remodeling, and vascular contractility. Endogenous peptide ligands for these GPCRs are of intermediate length (27–44 aa) and include receptor affinity (C-terminal) as well as receptor activation (N-terminal) domains. We have developed a technology in which a peptide ligand tethered to the cell membrane selectively modulates corresponding class B1 GPCR-mediated signaling. The engineered cDNA constructs encode a single protein composed of (i) a transmembrane domain (TMD) with an intracellular C terminus, (ii) a poly(asparagine-glycine) linker extending from the TMD into the extracellular space, and (iii) a class B1 receptor ligand positioned at the N terminus. We demonstrate that membrane-tethered peptides, like corresponding soluble ligands, trigger dose-dependent receptor activation. The broad applicability of this approach is illustrated by experiments using tethered versions of 7 mammalian endogenous class B1 GPCR agonists. In parallel, we carried out mutational studies focused primarily on incretin ligands of the glucagon-like peptide-1 receptor. These experiments suggest that tethered ligand activity is conferred in large part by the N-terminal domain of the peptide hormone. Follow-up studies revealed that interconversion of tethered agonists and antagonists can be achieved with the introduction of selected point mutations. Such complementary receptor modulators provide important new tools for probing receptor structure–function relationships as well as for future studies aimed at dissecting the tissue-specific biological role of a GPCR in vivo (e.g., in the brain vs. in the periphery).
- 12 May 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (19) , 8049-8054
Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function
Class B1 (secretin family) G protein-coupled receptors (GPCRs) modulate a wide range of physiological functions, including glucose homeostasis, feeding behavior, fat deposition, bone remodeling, and vascular contractility. Endogenous peptide ligands for these GPCRs are of intermediate length (27–44 aa) and include receptor affinity (C-terminal) as well as receptor activation (N-terminal) domains. We have developed a technology in which a peptide ligand tethered to the cell membrane selectively modulates corresponding class B1 GPCR-mediated signaling. The engineered cDNA constructs encode a single protein composed of (i) a transmembrane domain (TMD) with an intracellular C terminus, (ii) a poly(asparagine-glycine) linker extending from the TMD into the extracellular space, and (iii) a class B1 receptor ligand positioned at the N terminus. We demonstrate that membrane-tethered peptides, like corresponding soluble ligands, trigger dose-dependent receptor activation. The broad applicability of this approach is illustrated by experiments using tethered versions of 7 mammalian endogenous class B1 GPCR agonists. In parallel, we carried out mutational studies focused primarily on incretin ligands of the glucagon-like peptide-1 receptor. These experiments suggest that tethered ligand activity is conferred in large part by the N-terminal domain of the peptide hormone. Follow-up studies revealed that interconversion of tethered agonists and antagonists can be achieved with the introduction of selected point mutations. Such complementary receptor modulators provide important new tools for probing receptor structure–function relationships as well as for future studies aimed at dissecting the tissue-specific biological role of a GPCR in vivo (e.g., in the brain vs. in the periphery).